Trials / Completed
CompletedNCT02753803
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg
A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
A randomized, open-label, multiple dosing, three-way crossover clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of evogliptin 5 mg and pioglitazone 30 mg after oral administration in healthy male subjects
Detailed description
A randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence, crossover study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evogliptin, Pioglitazone, Evogliptin+Pioglitazone | Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD |
| DRUG | Pioglitazone, Evogliptin, Evogliptin+Pioglitazone | Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD |
| DRUG | Evogliptin, Evogliptin+Pioglitazone, Pioglitazone | Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD |
| DRUG | Pioglitazone, Evogliptin+Pioglitazone, Evogliptin | Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD |
| DRUG | Evogliptin+Pioglitazone, Evogliptin, Pioglitazone | Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD |
| DRUG | Evogliptin+Pioglitazone, Pioglitazone, Evogliptin | Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD |
Timeline
- Start date
- 2016-07-27
- Primary completion
- 2016-10-19
- Completion
- 2017-03-10
- First posted
- 2016-04-28
- Last updated
- 2017-09-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02753803. Inclusion in this directory is not an endorsement.